Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06369220
Other study ID # LIA-STI-542
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 15, 2024
Est. completion date October 31, 2024

Study information

Verified date June 2024
Source Hoffmann-La Roche
Contact Babar Javed, MBA
Phone 925-596-8295
Email babar.javed@roche.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).


Description:

The study is designed as a block randomized, controlled 2-arm prospective study. The study targets to enroll approximatively 348 participants at increased risk of sexually transmitted infections (STIs)-participants who have known contact with CT/NG/MG (including participants who report knowledge or suspicion of STI exposure, despite the uncertainty of the specific STI pathogen or contact testing results), or participants with symptoms suggestive of STI-to participate in this study. Participants who give consent will provide demographic information and urogenital specimen(s) for CT/NG/MG testing on the cobas® liat system and for external laboratory-polymerase chain reaction (EL-PCR) testing. Participants will be randomized in a 1:1 ratio in blocks (of multiples of 2) stratified by the site to either of the following arms: - Standard of Care (SOC) - Point of Care (POC) In both arms, the clinician will see and evaluate the participant and will complete a standardized form, known as a patient management plan (PMP), at the conclusion of the participant's encounter. The critical difference between the arms is that the clinician in the POC arm will be provided POC test results upon which they may choose to base their clinical decisions, whereas the SOC arm will not receive POC test results.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 348
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sexually active people - People seeking medical services for symptoms consistent with a sexually transmitted infection (STI) and/or known exposure to an STI Exclusion Criteria: - Previously enrolled in the study - Unable to provide informed consent - Currently pregnant - Declines POC testing - Presents for routine STI screening (asymptomatic) - Use of antimicrobial agents active against CT, NG, or MG during the 21 days before sample collection. Example of such antimicrobial agents include the following: Macrolides (e.g., azithromycin and erythromycin); Penicillins (e.g., amoxicillin); Tetracyclines (e.g., doxycycline); Fluoroquinolones (e.g., ciprofloxacin, ofloxacin, levofloxacin, and moxifloxacin); Cephalosporins (e.g., ceftriaxone and cefixime) - Use of phenazopyridine-containing urinary pain relief medicines (ie, Azo or Pyridium) within 2 days prior to sample collection - Use of any over-the-counter feminine hygiene products (internally or externally), such as vaginal moisturizers, lubricants (e.g., Replens, RepHresh, etc.), and feminine washes/vaginal douches, etc. within the 3 days prior to sample collection. The use of tampons or pads during menses is not an exclusionary criterion. - Contraindication to vaginal swab sampling where vaginal swab sampling is the only option available - Urination within 1 hour prior to sample collection (for subjects providing urine sample)

Study Design


Intervention

Diagnostic Test:
cobas® liat CT/NG/MG nucleic acid test
The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
Other:
Standard of Care (SOC): Clinician's Standard Practice
Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Hoffmann-La Roche Roche Molecular Systems, Inc

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Given Inappropriate Treatments for All Pathogens Combined (CT, NG, and MG) An inappropriate treatment is defined as under and/or overtreatment on the day of the medical encounter based on CDC recommendations for the pathogen-specific results obtained by EL-PCR. On the day of the medical encounter (Day 1)
Secondary Percentage of Participants Given Inappropriate Treatment for CT Infection On the day of the medical encounter (Day 1)
Secondary Percentage of Participants Given Inappropriate Treatment for NG Infection On the day of the medical encounter (Day 1)
Secondary Percentage of Participants Given Inappropriate Treatment for MG Infection On the day of the medical encounter (Day 1)
Secondary Mean Satisfaction and Confidence Rating Scores of SOC and POC, According to Healthcare Professionals' Responses to the CSDT Questionnaire Healthcare professionals will rate their confidence in and their satisfaction with the POC test and SOC procedures on a 5-point scale from very confident to very unconfident and on a 5-point scale from very satisfied to very dissatisfied, respectively, in response to the Clinician Satisfaction with Diagnostic Test Questionnaire (CSDT-Q). Once every 2 weeks until end of study (approximately 4 months)
Secondary Mean Satisfaction Rating Scores of SOC and POC, According to Participants' Responses to the PSDT Questionnaire Participants will rate their satisfaction with the POC test and SOC procedures on a 5-point scale from very satisfied to very dissatisfied in response to the Patient Satisfaction with Diagnostic Test Questionnaire (PSDT-Q). On the day of the medical encounter (Day 1)
See also
  Status Clinical Trial Phase
Completed NCT04269434 - GonoScreen: Efficacy of Screening STIs in MSM N/A
Active, not recruiting NCT04139629 - Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI N/A
Completed NCT03107377 - Phase 2B/3 Double-blinded Placebo-controlled Phase 2/Phase 3
Completed NCT03098329 - Check it: A New Approach to Controlling Chlamydia Transmission in Young People N/A
Recruiting NCT03862495 - Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT N/A
Completed NCT05307991 - Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Terminated NCT02083276 - Mecillinam for Treatment of Genital Chlamydia Infection Phase 2
Active, not recruiting NCT06131749 - Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
Completed NCT03568695 - Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction (PCR) After Pooling Pharyngeal, Anorectal and Urinary Samples N/A
Completed NCT01448876 - Incubation Time and Test of Cure of Chlamydia Trachomatis N/A
Not yet recruiting NCT06395675 - Clinical Evaluation of the ID NOW™ CT/NG Test N/A
Completed NCT03970850 - NeuMoDx PrEDiCTiNG Study Evaluation Plan N/A
Completed NCT01631201 - Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women Phase 2
Completed NCT05216744 - Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Phase 2
Recruiting NCT05581160 - Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST) N/A
Not yet recruiting NCT03532464 - Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Phase 4
Not yet recruiting NCT06234943 - Pharmacy-based Testing and Treatment for Gonorrhea and Chlamydia N/A
Active, not recruiting NCT04050540 - Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Phase 4
Completed NCT04955717 - Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences N/A
Active, not recruiting NCT05666778 - Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs Phase 2